Which has stronger earnings & valuation, CMPX or ONCY?

Compass Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Therapeutics N/A N/A -$66.49M -$0.41 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is CMPX or ONCY more profitable?

Compass Therapeutics' return on equity of -39.75% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -39.75% -35.29% Oncolytics Biotech N/A -2,185.97% -321.54%

Does the media prefer CMPX or ONCY?

In the previous week, Compass Therapeutics had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Compass Therapeutics and 2 mentions for Oncolytics Biotech. Compass Therapeutics' average media sentiment score of 0.97 beat Oncolytics Biotech's score of 0.94 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ONCY or ELYM?

Oncolytics Biotech presently has a consensus price target of $8.50, indicating a potential upside of 946.54%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, ONCY or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is ONCY or ELYM more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -321.54% Eliem Therapeutics N/A -47.03% -45.97%

Does the media refer more to XFOR or ONCY?

In the previous week, X4 Pharmaceuticals and X4 Pharmaceuticals both had 2 articles in the media. X4 Pharmaceuticals' average media sentiment score of 1.87 beat Oncolytics Biotech's score of 0.94 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oncolytics Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ONCY or DMAC?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A DiaMedica Therapeutics N/A N/A -$32.77M -$0.71 N/A

Is ONCY or DMAC more profitable?

DiaMedica Therapeutics' return on equity of -77.15% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -321.54% DiaMedica Therapeutics N/A -77.15% -69.23%

Does the media favor ONCY or UPB?

In the previous week, Upstream Bio had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Upstream Bio and 2 mentions for Oncolytics Biotech. Upstream Bio's average media sentiment score of 1.80 beat Oncolytics Biotech's score of 0.94 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Oncolytics Biotech (ONCY) Competitors

$0.81 -0.04 (-4.26%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.83 +0.02 (+2.44%)

As of 07/24/2026 07:34 PM Eastern

Compare

ONCY vs. CMPX, ELYM, XFOR, DMAC, and UPB

Should you buy Oncolytics Biotech stock or one of its competitors? MarketBeat compares Oncolytics Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncolytics Biotech include Compass Therapeutics (CMPX), Eliem Therapeutics (ELYM), X4 Pharmaceuticals (XFOR), DiaMedica Therapeutics (DMAC), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

How does Oncolytics Biotech compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Compass Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.41	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Compass Therapeutics currently has a consensus target price of $12.25, indicating a potential upside of 491.79%. Oncolytics Biotech has a consensus target price of $8.50, indicating a potential upside of 946.54%. Given Oncolytics Biotech's higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Compass Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Compass Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Compass Therapeutics' return on equity of -39.75% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

In the previous week, Compass Therapeutics had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Compass Therapeutics and 2 mentions for Oncolytics Biotech. Compass Therapeutics' average media sentiment score of 0.97 beat Oncolytics Biotech's score of 0.94 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Therapeutics beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks.

How does Oncolytics Biotech compare to Eliem Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Oncolytics Biotech had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Oncolytics Biotech and 0 mentions for Eliem Therapeutics. Oncolytics Biotech's average media sentiment score of 0.94 beat Eliem Therapeutics' score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Oncolytics Biotech	Positive
Eliem Therapeutics	Neutral

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oncolytics Biotech has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Eliem Therapeutics' return on equity of -47.03% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Oncolytics Biotech presently has a consensus price target of $8.50, indicating a potential upside of 946.54%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Oncolytics Biotech beats Eliem Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

X4 Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Oncolytics Biotech has lower revenue, but higher earnings than X4 Pharmaceuticals. Oncolytics Biotech is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.34	-$79.20M	-$4.54	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

X4 Pharmaceuticals currently has a consensus target price of $9.70, indicating a potential upside of 151.95%. Oncolytics Biotech has a consensus target price of $8.50, indicating a potential upside of 946.54%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oncolytics Biotech has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

In the previous week, X4 Pharmaceuticals and X4 Pharmaceuticals both had 2 articles in the media. X4 Pharmaceuticals' average media sentiment score of 1.87 beat Oncolytics Biotech's score of 0.94 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

X4 Pharmaceuticals beats Oncolytics Biotech on 8 of the 15 factors compared between the two stocks.

How does Oncolytics Biotech compare to DiaMedica Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

DiaMedica Therapeutics' return on equity of -77.15% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
DiaMedica Therapeutics	N/A	-77.15%	-69.23%

In the previous week, Oncolytics Biotech had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 2 mentions for Oncolytics Biotech and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.87 beat Oncolytics Biotech's score of 0.94 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncolytics Biotech	Positive
DiaMedica Therapeutics	Very Positive

Oncolytics Biotech has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Oncolytics Biotech currently has a consensus price target of $8.50, suggesting a potential upside of 946.54%. DiaMedica Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 78.04%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Oncolytics Biotech is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A

Summary

Oncolytics Biotech beats DiaMedica Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Upstream Bio?

Oncolytics Biotech (NASDAQ:ONCY) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Oncolytics Biotech presently has a consensus target price of $8.50, indicating a potential upside of 946.54%. Upstream Bio has a consensus target price of $33.17, indicating a potential upside of 417.42%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Oncolytics Biotech has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

In the previous week, Upstream Bio had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Upstream Bio and 2 mentions for Oncolytics Biotech. Upstream Bio's average media sentiment score of 1.80 beat Oncolytics Biotech's score of 0.94 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Oncolytics Biotech has higher earnings, but lower revenue than Upstream Bio. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Upstream Bio	$3.32M	105.01	-$143.44M	-$2.91	N/A

6.8% of Oncolytics Biotech shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Oncolytics Biotech has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

Summary

Upstream Bio beats Oncolytics Biotech on 9 of the 16 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCY vs. The Competition

Export

Metric	Oncolytics Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$101.25M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-2.62	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.08	89.45
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-20.31	7.88	10.28	6.07
Net Income	-$28.76M	$23.86M	$3.60B	$331.99M
7 Day Performance	-4.82%	-3.82%	-1.27%	-0.63%
1 Month Performance	-11.75%	-2.61%	-0.37%	-2.00%
1 Year Performance	-22.65%	32.79%	18.30%	13.62%

Oncolytics Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCY Oncolytics Biotech	2.1781 of 5 stars	$0.81 -4.3%	$8.50 +946.5%	-28.8%	$101.25M	N/A	N/A	30	Upcoming Earnings Gap Down
CMPX Compass Therapeutics	2.2934 of 5 stars	$2.26 -3.0%	$12.25 +442.0%	-34.5%	$419.61M	$850K	N/A	20	Positive News
ELYM Eliem Therapeutics	N/A	$14.00 +1.3%	N/A	+762.2%	$416.53M	N/A	N/A	9	High Trading Volume
XFOR X4 Pharmaceuticals	2.8776 of 5 stars	$4.05 -8.2%	$9.70 +139.5%	+110.4%	$415.95M	$35.11M	N/A	80	News Coverage Positive News
DMAC DiaMedica Therapeutics	1.7056 of 5 stars	$7.49 -2.3%	$12.33 +64.7%	+38.1%	$413.29M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCY) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncolytics Biotech (ONCY) Competitors

ONCY vs. CMPX, ELYM, XFOR, DMAC, and UPB

How does Oncolytics Biotech compare to Compass Therapeutics?

Summary

How does Oncolytics Biotech compare to Eliem Therapeutics?

Summary

How does Oncolytics Biotech compare to X4 Pharmaceuticals?

Summary

How does Oncolytics Biotech compare to DiaMedica Therapeutics?

Summary

How does Oncolytics Biotech compare to Upstream Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncolytics Biotech (ONCY) Competitors

ONCY vs. CMPX, ELYM, XFOR, DMAC, and UPB

How does Oncolytics Biotech compare to Compass Therapeutics?

Which has stronger earnings & valuation, CMPX or ONCY?

Do analysts rate CMPX or ONCY?

Which has more volatility and risk, CMPX or ONCY?

Do institutionals & insiders believe in CMPX or ONCY?

Is CMPX or ONCY more profitable?

Does the media prefer CMPX or ONCY?

Summary

How does Oncolytics Biotech compare to Eliem Therapeutics?

Does the media favor ONCY or ELYM?

Do insiders & institutionals have more ownership in ONCY or ELYM?

Which has more risk & volatility, ONCY or ELYM?

Which has preferable earnings and valuation, ONCY or ELYM?

Is ONCY or ELYM more profitable?

Do analysts rate ONCY or ELYM?

Summary

How does Oncolytics Biotech compare to X4 Pharmaceuticals?

Which has more volatility & risk, XFOR or ONCY?

Which has stronger valuation and earnings, XFOR or ONCY?

Do analysts rate XFOR or ONCY?

Do institutionals and insiders have more ownership in XFOR or ONCY?

Is XFOR or ONCY more profitable?

Does the media refer more to XFOR or ONCY?

Summary

How does Oncolytics Biotech compare to DiaMedica Therapeutics?

Is ONCY or DMAC more profitable?

Does the media prefer ONCY or DMAC?

Which has more risk and volatility, ONCY or DMAC?

Do analysts rate ONCY or DMAC?

Do institutionals & insiders hold more shares of ONCY or DMAC?

Which has preferable valuation & earnings, ONCY or DMAC?

Summary

How does Oncolytics Biotech compare to Upstream Bio?

Do analysts recommend ONCY or UPB?

Is ONCY or UPB more profitable?

Does the media favor ONCY or UPB?

Which has better valuation & earnings, ONCY or UPB?

Do institutionals and insiders believe in ONCY or UPB?

Which has more risk & volatility, ONCY or UPB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools